BTC 
ETH 
BNB 
XRP 
SOL 
TRX Amgen says Imdelltra-Imfinzi combo cut death risk 58% in Phase 3 SCLC trial
Amgen announced Phase 3 trial results showing that combining Imdelltra with Imfinzi reduced the risk of death by 58% in patients with small-cell lung cancer compared with Imfinzi alone, according to a post citing a CNBC article. The post states median overall survival was 21.1 months with the combination versus 12.7 months with Imfinzi alone. The post says the results could be significant for Amgen's oncology business, depending on regulatory approval, commercial adoption, and the treatment's safety profile.
Why “Rumor”
- Only community or trader posts: r/stocks
0 independent source groups across 1 post · evidence score 9/100. How labels work
What the sources claim
-
Amgen announced Phase 3 results showing the Imdelltra-Imfinzi combination reduced the risk of death by 58% versus Imfinzi alone in small-cell lung cancer.
“combining Imdelltra with Imfinzi reduced the risk of death by 58% in patients with small-cell lung cancer”
r/stocks -
Median overall survival was 21.1 months with the combination versus 12.7 months with Imfinzi alone.
“Median overall survival was 21.1 months with the combination versus 12.7 months with Imfinzi alone.”
r/stocks -
The significance for Amgen's oncology business depends on regulatory approval, commercial adoption, and the treatment's safety profile.
“depending on regulatory approval, commercial adoption, and the treatment’s safety profile”
r/stocks
Sources
More in Stocks & Indices
Summary and claims extracted by AI with prompt analyze-story@5 on 2026-10-25 03:10 UTC. Labels are computed from the sources, not by the model.